Haleon PLC
HLN10.130USD
+0.030+0.30%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
91.01BCap. mercado
41.39P/E TTM
Más Datos de Haleon PLC Compañía
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
Información de Haleon PLC
Símbolo de cotizaciónHLN
Nombre de la empresaHaleon PLC
Fecha de salida a bolsaJul 18, 2022
Director ejecutivoMcnamara (Brian)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJul 18
DirecciónBuilding 5, First Floor
CiudadWEYBRIDGE
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited Kingdom
Código postalKT13 0NY
Teléfono441932822000
Sitio Webhttps://www.haleon.com/
Símbolo de cotizaciónHLN
Fecha de salida a bolsaJul 18, 2022
Director ejecutivoMcnamara (Brian)
Ejecutivos de Haleon PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
446.70K
+0.46%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Matt Shattock
Mr. Matt Shattock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Ms. Tracy Clarke
Ms. Tracy Clarke
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Sir Dave Lewis
Sir Dave Lewis
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Keith Choy
Mr. Keith Choy
President, Asia Pacific
President, Asia Pacific
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
446.70K
+0.46%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Matt Shattock
Mr. Matt Shattock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Oral health
848.00M
32.28%
Pain relief
625.00M
23.79%
Respiratory health
428.00M
16.29%
Vitamins, minerals and supplements
417.00M
15.87%
Therapeutic Skin Health and Other
249.00M
9.48%
Digestive health and other
60.00M
2.28%
Por regiónUSD
Nombre
Ganancia
Proporción
EMEA and LatAm
1.12B
42.67%
Northern America
871.00M
33.16%
APAC
635.00M
24.17%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Oral health
848.00M
32.28%
Pain relief
625.00M
23.79%
Respiratory health
428.00M
16.29%
Vitamins, minerals and supplements
417.00M
15.87%
Therapeutic Skin Health and Other
249.00M
9.48%
Digestive health and other
60.00M
2.28%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Dodge & Cox
3.47%
Fidelity Management & Research Company LLC
2.00%
ClearBridge Investments, LLC
0.75%
Harding Loevner LP
0.40%
Wellington Management Company, LLP
0.35%
Otro
93.03%
Accionistas
Accionistas
Proporción
Dodge & Cox
3.47%
Fidelity Management & Research Company LLC
2.00%
ClearBridge Investments, LLC
0.75%
Harding Loevner LP
0.40%
Wellington Management Company, LLP
0.35%
Otro
93.03%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
5.67%
Investment Advisor
5.07%
Research Firm
0.76%
Hedge Fund
0.59%
Bank and Trust
0.17%
Family Office
0.07%
Family Office
0.06%
Family Office
0.06%
Individual Investor
0.02%
Otro
87.54%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1049
570.14M
12.80%
-16.29M
2025Q2
1049
577.49M
12.86%
-190.91M
2025Q1
1077
574.94M
12.79%
-194.57M
2024Q4
1094
745.67M
16.47%
-9.34M
2024Q3
1096
717.29M
15.74%
-81.04M
2024Q2
1078
719.27M
15.75%
-155.43M
2024Q1
1041
707.36M
15.49%
-53.58M
2023Q4
993
691.96M
14.98%
-58.05M
2023Q3
933
688.70M
14.92%
-37.88M
2023Q2
891
677.74M
14.68%
-44.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Dodge & Cox
155.47M
3.49%
-13.68M
-8.09%
Jun 30, 2025
Fidelity Management & Research Company LLC
97.52M
2.19%
+357.98K
+0.37%
Jun 30, 2025
ClearBridge Investments, LLC
31.45M
0.71%
-1.15M
-3.52%
Jun 30, 2025
Harding Loevner LP
22.55M
0.51%
-520.88K
-2.26%
Jun 30, 2025
Wellington Management Company, LLP
13.09M
0.29%
-122.94K
-0.93%
Sep 23, 2025
Fidelity Institutional Asset Management
14.24M
0.32%
-53.53K
-0.37%
Jun 30, 2025
Sculptor Capital Management, Inc
9.95M
0.22%
-900.00K
-8.30%
Jun 30, 2025
Managed Account Advisors LLC
10.98M
0.25%
+6.14M
+127.05%
Jun 30, 2025
Douglas C. Lane & Associates
8.18M
0.18%
-431.27K
-5.01%
Jun 30, 2025
Aristotle Capital Management, LLC
8.20M
0.18%
-241.03K
-2.86%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
VanEck Pharmaceutical ETF
6.34%
Franklin ClearBridge Enhanced Income ETF
1.87%
One Global ETF
0.65%
ActivePassive International Equity ETF
0.33%
SP Funds S&P World (ex-US) ETF
0.27%
Avantis Responsible International Equity ETF
0.13%
Avantis International Equity ETF
0.08%
Avantis International Large Cap Value ETF
0%
Unusual Whales Subversive Democratic Trading ETF
0%
Fidelity Blue Chip Value ETF
0%
Ver más
VanEck Pharmaceutical ETF
Proporción6.34%
Franklin ClearBridge Enhanced Income ETF
Proporción1.87%
One Global ETF
Proporción0.65%
ActivePassive International Equity ETF
Proporción0.33%
SP Funds S&P World (ex-US) ETF
Proporción0.27%
Avantis Responsible International Equity ETF
Proporción0.13%
Avantis International Equity ETF
Proporción0.08%
Avantis International Large Cap Value ETF
Proporción0%
Unusual Whales Subversive Democratic Trading ETF
Proporción0%
Fidelity Blue Chip Value ETF
Proporción0%
Dividendos
Un total de
570.00M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Aug 01, 2024
HLN.NB Final Cash Dividend of gross USD 0.051416 paid on Sep 19, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 19, 2024
Aug 16, 2024
Feb 29, 2024
HLN.NB Interim Cash Dividend of gross USD 0.105268 paid on May 16, 2024 going ex on Mar 14, 2024
Mar 15, 2024
May 16, 2024
Mar 14, 2024
Aug 02, 2023
HLN.NB Interim Cash Dividend of gross USD 0.043871 paid on Oct 05, 2023 going ex on Aug 24, 2023
Aug 25, 2023
Oct 05, 2023
Aug 24, 2023
Mar 02, 2023
HLN.NB Final Cash Dividend of gross USD 0.059732 paid on Apr 27, 2023 going ex on Mar 16, 2023
Mar 17, 2023
Apr 27, 2023
Mar 16, 2023
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Haleon PLC?
Los cinco principales accionistas de Haleon PLC son:
Dodge & Cox posee 155.47M acciones, lo que representa el 3.49% del total de acciones.
Fidelity Management & Research Company LLC posee 97.52M acciones, lo que representa el 2.19% del total de acciones.
ClearBridge Investments, LLC posee 31.45M acciones, lo que representa el 0.71% del total de acciones.
Harding Loevner LP posee 22.55M acciones, lo que representa el 0.51% del total de acciones.
Wellington Management Company, LLP posee 13.09M acciones, lo que representa el 0.29% del total de acciones.
Dodge & Cox posee 155.47M acciones, lo que representa el 3.49% del total de acciones.
Fidelity Management & Research Company LLC posee 97.52M acciones, lo que representa el 2.19% del total de acciones.
ClearBridge Investments, LLC posee 31.45M acciones, lo que representa el 0.71% del total de acciones.
Harding Loevner LP posee 22.55M acciones, lo que representa el 0.51% del total de acciones.
Wellington Management Company, LLP posee 13.09M acciones, lo que representa el 0.29% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Haleon PLC?
Los tres principales tipos de accionista de Haleon PLC son:
Dodge & Cox
Fidelity Management & Research Company LLC
ClearBridge Investments, LLC
Dodge & Cox
Fidelity Management & Research Company LLC
ClearBridge Investments, LLC
¿Cuántas instituciones poseen acciones de Haleon PLC (HLN)?
A fecha de 2025Q3, 1049 instituciones poseen acciones de Haleon PLC, con un valor de mercado combinado de aproximadamente 570.14M, lo que representa el 12.80% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -0.06%.
¿Cuál es la mayor fuente de ganancias de Haleon PLC?
El FY2025Q2, el segmento empresarial Oral health generó la ganancia más alta para Haleon PLC, ascendiendo a 848.00M y representando el 32.28% de la ganancia total.
